US20220000954A1 - Composition comprising elderberry extract as effective component for preventing, treating, or alleviating andropause syndrome - Google Patents
Composition comprising elderberry extract as effective component for preventing, treating, or alleviating andropause syndrome Download PDFInfo
- Publication number
- US20220000954A1 US20220000954A1 US17/289,893 US201917289893A US2022000954A1 US 20220000954 A1 US20220000954 A1 US 20220000954A1 US 201917289893 A US201917289893 A US 201917289893A US 2022000954 A1 US2022000954 A1 US 2022000954A1
- Authority
- US
- United States
- Prior art keywords
- extract
- elderberry
- decreased
- composition
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 66
- 235000008995 european elder Nutrition 0.000 title claims abstract description 53
- 241000208829 Sambucus Species 0.000 title claims abstract description 47
- 235000018735 Sambucus canadensis Nutrition 0.000 title claims abstract description 47
- 235000007123 blue elder Nutrition 0.000 title claims abstract description 47
- 235000007124 elderberry Nutrition 0.000 title claims abstract description 47
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims abstract description 92
- 229960003604 testosterone Drugs 0.000 claims abstract description 46
- 235000013305 food Nutrition 0.000 claims abstract description 21
- 230000003247 decreasing effect Effects 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 235000003142 Sambucus nigra Nutrition 0.000 claims description 6
- 240000006028 Sambucus nigra Species 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- -1 alkylene glycols Chemical class 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 210000003205 muscle Anatomy 0.000 claims description 5
- 206010022998 Irritability Diseases 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- 206010016256 fatigue Diseases 0.000 claims description 4
- 230000001568 sexual effect Effects 0.000 claims description 4
- 208000019116 sleep disease Diseases 0.000 claims description 4
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000006820 Arthralgia Diseases 0.000 claims description 3
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 206010024264 Lethargy Diseases 0.000 claims description 3
- 208000000112 Myalgia Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 230000002996 emotional effect Effects 0.000 claims description 3
- 150000008282 halocarbons Chemical class 0.000 claims description 3
- 230000037315 hyperhidrosis Effects 0.000 claims description 3
- 230000009610 hypersensitivity Effects 0.000 claims description 3
- 230000001771 impaired effect Effects 0.000 claims description 3
- 208000013465 muscle pain Diseases 0.000 claims description 3
- 208000020685 sleep-wake disease Diseases 0.000 claims description 3
- 230000028327 secretion Effects 0.000 abstract description 28
- 238000010171 animal model Methods 0.000 abstract description 6
- 241000700159 Rattus Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 210000002332 leydig cell Anatomy 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 241001618264 Rubus coreanus Species 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 230000007423 decrease Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 235000021028 berry Nutrition 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000000469 ethanolic extract Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960001031 glucose Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000001727 glucose Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010058359 Hypogonadism Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 244000297531 Lespedeza cuneata Species 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 231100001092 no hepatotoxicity Toxicity 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002261 Androgen deficiency Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000208828 Caprifoliaceae Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 241000759833 Cornus officinalis Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 244000151637 Sambucus canadensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000312 effect on influenza Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000009986 erectile function Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 201000003585 eunuchism Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000003803 hair density Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 108010030696 low density lipoprotein triglyceride Proteins 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 208000037106 male hypogonadism Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a composition comprising an elderberry extract as an effective component for preventing, treating, or alleviating andropause syndrome, wherein the elderberry extract of the present invention increases testosterone secretion in sperm cells and andropause syndrome animal models, and thus can be usefully employed as a pharmaceutical or food composition for preventing, treating or alleviating andropause syndrome.
Description
- The present invention relates to a composition for preventing, treating or alleviating andropause syndrome, which includes an elderberry extract as an active ingredient.
- The change in the endocrine system such as menopause occurring in females is called male climacteric since it occurs in males, and this term was first used for the syndrome similar to female climacteric by Werner in 1939.
- Men have no menopause like women, but the decrease in androgen increases with age and decreases by 0.2 to 2.0% every year. From the age of 40 to 50, male hormone secretion gradually decreases, and decreases to ½ of the level in the 30s in the 70s and ⅓ of that in the 80s, thereby reducing the sensitivity of target cells to testosterone, which is an active androgen, and exhibiting several climacteric symptoms like women.
- When testosterone in the body is below the normal range (12 nmol/L or 350 ng/dL or more), it is called male hypogonadism, and when a hormone level is lowered due to dysfunction of the pituitary-hypothalamus-testicular axis that produces male hormones as a man ages, it is called late-onset hypogonadism (LOH). According to the Korean Male Menopause Society, male climacteric is defined as a clinical and biochemical syndrome that accompanies typical symptoms experienced with aging in men and serum testosterone deficiency to reduce the quality of life and cause an adverse effect on the functions of various organs, and it is academically referred to as late onset hypogonadism (LOH), and generally referred to as andropause syndrome.
- The andropause syndrome is closely related to the decrease in testosterone, and includes all of total testosterone, free testosterone, and protein-binding testosterone. After a man turns 40, testosterone produced from the testis or adrenal glands decreases, resulting in a decrease in serum total testosterone and free testosterone and albumin-binding testosterone by 0.4%, 10% or 12% per year. Drinking alcohol is known to reduce the secretion of testosterone by destruction of cells in the testis by acetaldehyde, which is an alcohol-degrading substance, and smoking also decreases testosterone secretion to increase the occurrence of the climacteric syndrome.
- Symptoms of the andropause syndrome may include physical decreases in muscle mass and strength, body fat mass and hair and bone density and an increase in visceral fat, and mentally decreases in intellectual activity, cognitive function and spatial orientation, a change in mood such as fatigue, depression and irritability, and sleep disorders. A sexual change is characterized by decreased sexual desire and erectile function. However, the andropause syndrome does not only have the problem of impotence, but also various accompanying symptoms such as dyslipidemia, cardiovascular disease, abdominal obesity, decreased muscle strength, decreased bone density, decreased motivation, and decreased memory and concentration, and when these symptoms are neglected, the quality of life may be threatened.
- Meanwhile, elderberry is a stoloniferous and deciduous broad-leaved shrub of the family Caprifoliaceae, and mainly lives along rivers and in woodlands, grows in various soils and well-drained sunny areas, and has cold resistance and moisture resistance to be able to survive even at −20° C. Elderberry is called golden strawberry or golden grape in Korea, contains proteins, carbohydrates, tannin, vitamin C, and various minerals such as potassium, magnesium and calcium and large amounts of polyphenols, anthocyanins and flavonols in its fruits. Due to a high antioxidant property, elderberry has been used as a cold remedy in home remedies, and is known to be effective for diarrhea, abdominal pain, rheumatoid and antimutagenicity.
- Korean Patent No. 10-1870940: Health food composition for improving andropause syndrome, containing Lespedeza cuneata and red ginseng
- Korean Unexamined Patent Application Publication No. 2018-0111317: Composition for preventing, alleviating and treating andropause syndrome, containing composite extract of Cornus officinalis, Pueraria root and Lespedeza cuneata as active ingredient
- The inventors studied berry extracts to develop a therapeutic agent effective for andropause syndrome, and thus confirmed that an elderberry extract among the berry extracts increases testosterone secretion in Leydig cells and andropause animal models, and therefore, the present invention was completed.
- Accordingly, the present invention is directed to providing a composition for preventing, treating or alleviating andropause syndrome.
- To attain the above-described purpose, the present invention provides
- a composition for preventing or treating andropause syndrome, which includes an elderberry (Sambucus nigra) extract as an active ingredient.
- In addition, the present invention provides
- a food composition for preventing or alleviating andropause syndrome, which contains an elderberry (Sambucus nigra) extract as an active ingredient.
- Since an elderberry extract of the present invention has an excellent effect to alleviating andropause syndrome through a mechanism of increasing a secretion amount of testosterone, which is a male hormone, in Leydig cells as well as andropause syndrome animal model, a composition of the present invention including the extract as an active ingredient can also have an effect of preventing, treating or alleviating andropause syndrome and thus can be effectively used as a pharmaceutical or food composition.
-
FIG. 1 shows the result of confirming the testosterone secretion capacity of Leydig cells according to the treatment of hydrothermal and ethanol extracts of other types of berries and an elderberry extract. -
FIG. 2 shows the result of confirming the testosterone secretion capacity according to the concentration-dependent treatment of an elderberry hydrothermal extract in Leydig cells. -
FIG. 3 shows the result of confirming the testosterone secretion capacity according to the concentration-dependent treatment of an elderberry hydrothermal extract in Leydig cells. -
FIG. 4 shows the result of confirming the effect of improving the testosterone secretion capacity according to the treatment of an elderberry hydrothermal extract in elderly animal models. - Hereinafter, the present invention will be described in detail.
- The present invention provides a pharmaceutical composition for preventing or treating andropause syndrome, which includes an elderberry (Sambucus nigra) extract as an active ingredient.
- Elderberry (Sambucus nigra) is a preparation called sambucol, which is widely known to have an effect on influenza virus-mediated diseases, but the association with andropause syndrome has not yet been reported.
- The andropause syndrome defined in the present invention includes joint or muscle pain, osteoporosis, hyperhidrosis, a sleep disorder, erethism, hypersensitivity, emotional anxiety, lethargy, fatigue, decreased muscle strength, depression, decreased sexual energy, decreased libido, impaired erection, aging, and a decreased genitourinary function.
- As a result of a comparative experiment to confirm a testosterone secretion effect in Leydig cells of an elderberry extract according to the present invention with a Rubus coreanus water extract and a Rubus coreanus ethanol extract, it can be confirmed that the elderberry extract has superior testosterone secretion efficacy.
- The composition of the present invention increases a blood testosterone content.
- In the present invention, the elderberry extract used as a raw material includes a elderberry solution obtained by infusion or brewing, a concentrate obtained by concentrating a part or all of the same, an extract prepared by drying the concentrate, and a chemical exhibiting the main effect, which is contained in the extract,
- The extract of the present invention may be prepared by a conventional method known in the art, for example, maceration, reflux cooling extraction, hydrothermal extraction, room temperature extraction, heat extraction, ultrasonic extraction or supercritical extraction, using a conventional solvent.
- Specifically, an extraction solvent selected from distilled water, C1-C6 alcohols, glycerin, C2-C6 alkylene glycols, C1-C6 alkanes, C1-C6 halogenated hydrocarbons, C2-C6 alkyl alkanoates, and a mixture thereof may be used. More specifically, an extraction solvent selected from distilled water, methanol, ethanol, 1,2-propanediol, glycerin, ethylene glycol, butylene glycol, propylene glycol, dichloromethane, dichloroethane, hexane, ethyl acetate and a mixture thereof may be used. Preferably, as a solvent, distilled water may be used.
- Here, the amount of the extraction solvent used herein may 5 to 30-fold, and preferably 5 to 20-fold the volume of the weight of a raw material.
- An extraction temperature may be selected in the range of various temperatures, for example, 20 to 100° C., which is suitable for an extraction method, by those of ordinary skill in the art, but the present invention is not limited thereto. In addition, an extraction time may vary according to an extraction method by those of ordinary skill in the art, but the present invention is not limited thereto. However, extraction may be performed once or several times for approximately 1 hour to several days. An extract obtained by extraction with a primary extraction solvent may be obtained in a liquid type from which impurities are removed by filtration according to a conventional method, or the liquid extract obtained thereby may be obtained in a powder type by reduced pressure concentration and/or drying according to a conventional method.
- In addition, to be used as a composition component, the extract according to the present invention may be a freeze-dried powder type, or a liquid type dispersed or dissolved in water or a conventional organic solvent.
- The pharmaceutical composition is preferably prepared by further including one or more types of pharmaceutically acceptable carriers in addition to the above-described active ingredient for administration. The composition of the present invention includes 0.01 to 99 wt % of the elderberry extract with respect to the total weight of the composition. However, the present invention is not limited thereto.
- The composition including the extract of the present invention may further include suitable carriers, excipients and diluents, which are conventionally used in the preparation of a pharmaceutical composition.
- The composition including the extract according to the present invention may be used after being formulated in an oral form such as a powder, granule, tablet, capsule, suspension, emulsion, syrup or aerosol, a preparation for external use, a suppository, or a sterile injectable solution, and as a carrier, an excipient and a diluent, which can be used herein, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propyhydroxybenzoate, magnesium stearate and mineral oil may be mentioned. For preparation, a normally used diluent or excipient such as a filler, a thickening agent, a binder, a wetting agent, a disintegrant, or surfactant is used. Solid preparations for oral administration include a tablet, a pill, a powder, a granule, and a capsule, and the solid preparation is prepared by mixing at least one excipient, such as at least starch, calcium carbonate, sucrose, lactose or gelatin with the extract. In addition, other than a simple excipient, lubricants such as magnesium stearate and talc may also be used.
- Liquid preparations for oral administration include a suspending agent, an oral liquid for external use, an emulsion and a syrup, and may include various excipients, for example, a wetting agent, a sweetening agent, a fragrance and a preservative, in addition to a frequently used simple diluent, such as water, a liquid or paraffin. Preparations for parenteral administration include a sterilized aqueous solution, a non-aqueous solvent, a suspension, an emulsion, a freeze-dried preparation, and a suppository. As a non-aqueous solvent or suspension, propylene glycol, polyethylene glycol, a vegetable oil such as olive oil, or an injectable ester such as ethyl oleate may be used. As a base for suppositories, Witepsol, Macrogol, Tween 61, cacao butter, laurin, or glycerogelatin may be used.
- A preferable dose of the extract of the present invention may vary according to the condition and body weight of a patient, the severity of a disease, a dosage form, or the route and duration of administration, but may be suitable selected by those of ordinary skill in the art. However, for a preferable effect, the extract may be administered at 0.01 mg/kg to 10 g/kg per day, and preferably 1 mg/kg to 1 g/kg per day. The daily dose may be administered once or in divided portions. Therefore, the dose does not limit the scope of the present invention in any way.
- The composition of the present invention may be administered to mammals such as a rat, a mouse, livestock, and a human by various routes. All routes of the administration may be expected, and for example, the administration may be performed orally, intrarectally or intravenously.
- In addition, the elderberry extract of the present invention may also be used as a food composition for preventing and alleviating andropause syndrome, and may be included at 0.01 to 95 wt %, and preferably, 1 to 80 wt % with respect to the total weight of the food composition.
- When the composition of the present invention is used as a food composition, in addition to the elderberry extract as an active ingredient, components that are conventionally added in food production, for example, a protein, a carbohydrate, fats, a nutrient, a seasoning and a flavoring agent may be further added.
- Examples of the carbohydrate include conventional sugars, for example, monosaccharides such as glucose and sucrose, disaccharides such as maltose, sucrose and oligosaccharides; and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. A flavoring agent may be a natural flavoring agent and a synthetic flavoring agent.
- The food composition of the present invention may be prepared by the same method as the pharmaceutical composition to prevent and alleviate andropause syndrome, and thus may be used as health functional food according to Health Functional Food Act No. 6727 or added to various types of food. In the case when the food composition is prepared for health functional food, the composition can be prepared and processed in a pharmaceutical dosage form such as a powder, a granule, a tablet, a capsule, a pill, a suspension, an emulsion, or a syrup, or in the form of a tea bag, an infused tea or a health drink. When added to various foods, there are no special limitation to the types of food. Examples of food to which the elderberry extract of the present invention may be added may include meat, sausage, bread, chocolate, candy, snacks, confectioneries, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and include all heath foods in a conventional sense.
- In the case when the food composition of the present invention is prepared in the form of a drink, in addition to the elderberry extract of the present invention, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid or fruit juice may be additionally included.
- In addition, the food composition may contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and a salt thereof, alginic acid and a salt thereof, an organic acid, a protective colloidal thickening agent, a pH adjuster, a stabilizer, a preservative, glycerin, an alcohol or a carbonating agent used for carbonated beverages in addition to the above-described component. Other than these, the food composition of the present invention may contain natural fruit juice, or a fruit pulp for producing beverages and vegetable beverages. These components may be used independently or in combination.
- Hereinafter, preferable examples and experimental examples of the present invention will be described. The following examples and experimental examples were merely described for the purpose of more clearly expressing the present invention, but the disclosure of the present invention is not limited to the following examples.
- 100 g of purchased fresh elderberries were added to a 10-fold amount of solvent (1 L) and extracted twice for 2 hours using a reflux cooling device-attached heating mantle, and filtration was performed twice with a 10 to 25-μm filter using a metal detector. Each extract was concentrated to 6.0 to 8.0 brix % using a vacuum concentrator, lyophilized to powder, and stored in a freezer at −20° C. In this experiment, the powdered extract was used after dissolution with distilled water (D.W) per concentration.
- A Rubus coreanus water extract was prepared in the same manner as Example 1, except that fresh berries of Rubus coreanus were used instead of fresh elderberries.
- A Rubus coreanus ethanol extract was prepared in the same manner as Example 1, except that fresh berries of Rubus coreanus were used instead of fresh elderberries, and 70% ethanol was used as an extraction solvent.
- 1) Culture of Leydig Cells
- Leydig TM3 cells were obtained from the American Type Culture Collection (ATCC). The Leydig cells were cultured in a CO2 incubator (Forma Scientific, Inc.) using a medium prepared by mixing Dulbecco Modified Eagle Medium (DMEM, high glucose) and Ham's F-12K (Kaighn's) Medium in a ratio of 1:1, and adding 2.5% fetal bovine serum (FBS), 5% horse serum and 1% penicillin-streptomycin. The cells were observed using a microscope to confirm stability, and then the cells were used in the experiment.
- 2) Evaluation of Testosterone Secretion Capacity in Leydig Cells
- TM3 cells were seeded at 1×105 cells/well in a 24-well culture plate, and then stabilized for 24 hours. Afterward, the medium was replaced with a serum-free medium, the extract was diluted according to a concentration (μg/mL) and treated in each well, and then after 24 hours, the medium of each well was recovered. The recovered medium was centrifuged to obtain a supernatant, and to confirm the concentration of testosterone in the supernatant, an assay was carried out based on the method suggested in a testosterone ELISA kit (Abeam®, ab108666, UK).
- Testosterone concentrations produced in the culture of Leydig cells treated with the extract of Example 1, the Rubus coreanus extracts of Comparative Examples 1 and 2 were measured using an ELISA kit, and the result is shown in
FIG. 1 . Referring toFIG. 1 , compared with a normal control, a testosterone secretion level was most highly increased in the group treated with the elderberry hydrothermal extract among the groups treated with the Rubus coreanus water extract. Rubus coreanus ethanol extract and elderberry hydrothermal extract, confirming that the elderberry hydrothermal extract has an effect on the testosterone secretion capacity. - To confirm the testosterone secretion effect according to the concentration of an extract, testosterone secretion levels in Leydig cells were measured by treating the elderberry hydrothermal extract at low concentrations (5, 10 and 20 μg/mL) and high concentrations (1, 25, 50 and 100 μg/mL). Referring to
FIGS. 2 and 3 , compared with the normal control, it was confirmed that the testosterone secretion capacity was concentration-dependently shown from 5 μg/mL or more of the extract, and secretion levels significantly increased. From these results, it was confirmed that the elderberry hydrothermal extract alleviates the andropause syndrome, which is one of the syndromes generated by a hormonal change, particularly, decreased testosterone, by increasing the testosterone secretion capacity in Leydig cells. - 1) Andropause Syndrome Animal Model and Summary of Test
- 23-week-old male SD rats (Samtako, Korea) were purchased and acclimated, and upon reaching a body weight of approximately 510 g (6-month-old), they were divided into 9 rats per experimental group. One week before the completion of the experiment, 11-week-old male SD rats (Samtako, Korea) were purchased and acclimated, followed by dividing them into 9 rats per group upon becoming 12 weeks old.
- Aa a control group, 6-month-old rats were used, and as an experimental group, elderly rats to which 300 mg/kg of an elderberry hydrothermal extract was orally administered once a day for 12 weeks so as to confirm an improvement in andropause syndrome were used.
- 2) Evaluation of Testosterone Secretion Capacity in Serum
- To analyze the testosterone secretion capacity in serum before autopsy, blood was obtained through jugular vein from rats of all experimental groups. Blood was coagulated for approximately 30 minutes, and then centrifuged for 5 minutes at 10,000 rpm to separate the serum. To confirm a testosterone level in serum after the separation of the serum, analysis was carried out based on a method suggested in a testosterone ELISA kit (Abcam®, ab108666, UK).
- As a result, compared with the control, a testosterone secretion level was increased, but not significantly, in the group to which the elderberry hydrothermal extract was orally administered, and therefore, it can be confirmed that the elderberry hydrothermal extract has an effect on the testosterone secretion effect (
FIG. 4 ). From these results, it can be confirmed that the elderberry hydrothermal extract increases the testosterone secretion capacity in elderly male rats such that the andropausesyndrome, which is one of the syndromes exhibited by a hormonal change, that is, reduced testosterone, is improved. - 3) Measurement of Changes in Hepatotoxicity, Lipoprotein and Triglyceride Levels
- Blood was obtained through an abdominal vein from rats of all groups at autopsy for analysis of biochemical markers in serum. The blood was coagulated for approximately 30 minutes, and then centrifuged for 5 minutes at 10,000 rpm to separate the serum. After separation of the serum, to confirm liver function (AST, ALT), lipoprotein (total cholesterol (T-CHO), HDL cholesterol (HDL-C), cholesterol (LDL-C)) and triglyceride levels, a biochemical analyzer (AU480, BeckmanCoulter, USA) was used, and the result is shown in Table 1.
-
TABLE 1 AST ALT Total cholesterol HDL LDL Triglyceride Classification (U/L) (U/L) (mg/dL) (mg/dL) (mg/dL) (mg/dL) Young rat control 99 ± 42 30 ± 5 65 ± 13 40 ± 7 20 ± 4 45 ± 10 Elderly rat control 94 ± 39 41 ± 22 106 ± 19 55 ± 8 36 ± 10 111 ± 44 Elderberry extract- 98 ± 52 30 ± 6 93 ± 35 49 ± 18 32 ± 10 74 ± 29 administered group - As a result, compared with the controls, it can be confirmed that there was no hepatotoxicity in the entire elderberry hydrothermal extract-administered group as there was no statistically significant change, and compared with the control of 12-week-old young rats, in the control of 6-month-old andropause rats, cholesterol and triglyceride levels significantly increased, but these increases were not significant but reduced due to the elderberry hydrothermal extract. From these results, it was confirmed that the elderberry hydrothermal extract has no hepatotoxicity, and is effective in reducing cholesterol and triglycerides.
- From the above-described results, it can be seen that the elderberry extract increases the testosterone secretion capacity in Leydig cells as well as andropause syndrome animals to have andropaus improvement efficacy.
Claims (8)
1. A pharmaceutical composition for preventing or treating andropause syndrome, comprising:
an elderberry (Sambucus nigra) extract as an active ingredient.
2. The pharmaceutical composition of claim 1 , wherein the andropause syndrome is joint or muscle pain, osteoporosis, hyperhidrosis, a sleep disorder, erethism, hypersensitivity, emotional anxiety, lethargy, fatigue, decreased muscle strength, depression, decreased sexual energy, decreased libido, impaired erection, aging or a decreased genitourinary function.
3. The pharmaceutical composition of claim 1 , which increases a blood testosterone content.
4. The pharmaceutical composition of claim 1 , wherein the extract is obtained using an extraction solvent selected from distilled water, C1-C6 alcohols, glycerin, C2-C6 alkylene glycols, C1-C6 alkanes, C1-C6 halogenated hydrocarbons, C2-C6 alkyl alkanoates, and a mixture thereof.
5. A food composition for preventing or improving andropause syndrome, comprising:
an elderberry (Sambucus nigra) extract as an active ingredient.
6. The food composition of claim 5 , wherein the andropause syndrome is joint or muscle pain, osteoporosis, hyperhidrosis, a sleep disorder, erethism, hypersensitivity, emotional anxiety, lethargy, fatigue, decreased muscle strength, depression, decreased sexual energy, decreased libido, impaired erection, aging or a decreased genitourinary function.
7. The food composition of claim 5 , which increases a blood testosterone content.
8. The food composition of claim 5 , wherein the extract is obtained using an extraction solvent selected from distilled water, C1-C6 alcohols, glycerin, C2-C6 alkylene glycols, C1-C6 alkanes, C1-C6 halogenated hydrocarbons, C2-C6 alkyl alkanoates, and a mixture thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0131431 | 2018-10-31 | ||
KR1020180131431A KR102080410B1 (en) | 2018-10-31 | 2018-10-31 | Composition for Preventing, Treating or Improving of Andropause Syndrome Comprising Elderberry Extracts |
PCT/KR2019/013465 WO2020091265A1 (en) | 2018-10-31 | 2019-10-15 | Composition comprising elderberry extract as effective component for preventing, treating, or alleviating male climacteric syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220000954A1 true US20220000954A1 (en) | 2022-01-06 |
Family
ID=69670980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/289,893 Pending US20220000954A1 (en) | 2018-10-31 | 2019-10-15 | Composition comprising elderberry extract as effective component for preventing, treating, or alleviating andropause syndrome |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220000954A1 (en) |
EP (1) | EP3875101B1 (en) |
JP (1) | JP7161064B2 (en) |
KR (1) | KR102080410B1 (en) |
CN (2) | CN113164541B (en) |
WO (1) | WO2020091265A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210108792A (en) | 2020-02-26 | 2021-09-03 | 정진철 | Composition for preventing or treating andropause related symptoms comprising natural extract as an active ingredient |
KR20230069853A (en) * | 2021-11-12 | 2023-05-19 | 주식회사 코사바이오 | Pharmaceutical composition for preventing or treating of muscle diseases |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109498599A (en) * | 2018-12-10 | 2019-03-22 | 徐州铂蓝新材料科技有限公司 | Daily health caring sustained-release gel ointment table |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1742775A (en) * | 2005-08-02 | 2006-03-08 | 孙毅 | Medicine composition for preventing and treating orthopedic diseases |
IL173207A0 (en) * | 2006-01-17 | 2006-06-11 | Healthcare Brands Internat Ltd | Treatment of avian flu with black elderberry extract |
CN101773490B (en) * | 2010-01-25 | 2013-02-20 | 香港理工大学深圳研究院 | Active part of Sambucus williamsii Hance for reducing risk of bone-related diseases of menopausal women and application thereof |
CN102153453A (en) * | 2010-02-11 | 2011-08-17 | 香港理工大学深圳研究院 | Sambucus williamsii hance lignan compound and preparation method and application thereof |
US20160206673A1 (en) * | 2015-01-15 | 2016-07-21 | David Miller | Composition and Method for Improving Sexual Performance |
KR101870940B1 (en) | 2016-04-15 | 2018-06-27 | 한국인스팜(주) | health food composition for improving andropause syndrome |
FR3054443B1 (en) * | 2016-07-28 | 2020-01-03 | Activ'inside | VERY CONCENTRATED PLANT EXTRACT IN SAFRANAL, PROCESS FOR OBTAINING AND USES |
KR20180111317A (en) | 2017-03-31 | 2018-10-11 | 한약진흥재단 | A composition preventing, improving and treating comprising extract of Cornus officinalis, Pueraria lobata root and Lespedeza cuneata |
-
2018
- 2018-10-31 KR KR1020180131431A patent/KR102080410B1/en active IP Right Grant
-
2019
- 2019-10-15 CN CN201980078591.5A patent/CN113164541B/en active Active
- 2019-10-15 CN CN202310182135.3A patent/CN116211911A/en active Pending
- 2019-10-15 EP EP19879715.1A patent/EP3875101B1/en active Active
- 2019-10-15 US US17/289,893 patent/US20220000954A1/en active Pending
- 2019-10-15 WO PCT/KR2019/013465 patent/WO2020091265A1/en unknown
- 2019-10-15 JP JP2021548486A patent/JP7161064B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109498599A (en) * | 2018-12-10 | 2019-03-22 | 徐州铂蓝新材料科技有限公司 | Daily health caring sustained-release gel ointment table |
Also Published As
Publication number | Publication date |
---|---|
KR102080410B1 (en) | 2020-02-21 |
JP7161064B2 (en) | 2022-10-25 |
EP3875101B1 (en) | 2023-09-27 |
CN113164541B (en) | 2024-01-05 |
WO2020091265A1 (en) | 2020-05-07 |
CN113164541A (en) | 2021-07-23 |
EP3875101A4 (en) | 2022-06-08 |
EP3875101A1 (en) | 2021-09-08 |
JP2022509468A (en) | 2022-01-20 |
CN116211911A (en) | 2023-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9649351B2 (en) | Anti-angiogenic agents and anti-obesity substances applied with anti-angiogenesis from natural products | |
KR101464337B1 (en) | Composition for anti-obesity comprising extract of Diospyros lotus as effective component | |
US20220000954A1 (en) | Composition comprising elderberry extract as effective component for preventing, treating, or alleviating andropause syndrome | |
US20070059393A1 (en) | Composition for inhibition or prevention of bone density | |
KR20150038775A (en) | A composition comprising the extract of Curcuma longa L for preventing and treating benign prostatic hyperplasia | |
KR20200085156A (en) | Composition for preventing or treating andropause related symptoms comprising the extract of rice bran | |
KR101820096B1 (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating metabolic disease | |
EP3144005A1 (en) | Composition for preventing and treating male infertility, containing mixed herbal extract as active ingredient and use thereof | |
KR101917363B1 (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating menopausal disorder | |
KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
KR101690369B1 (en) | Anti-obesity composition containing bitter melon mixture hot water extract and manufacturing method thereof | |
KR101070476B1 (en) | Composition containing extract of black onion for prevention and treatment of Gout or Hyperuricemia | |
KR101851639B1 (en) | Composition for anti-obesity comprising Chaenomelis Fructus extract or its fraction as effective component | |
KR101373653B1 (en) | A composition comprising the extract of Rosa rugosa for preventing and treating benign prostatic hyperplasia | |
KR100888068B1 (en) | Compositions for suppressing obesity | |
KR101406126B1 (en) | Composition containing Hedyotis diffusa extract for treating or preventing obesity | |
KR102464897B1 (en) | Herbal Compositions for Prevention, Improvement or Treatment of Benign Prostatic Hyperplasia | |
KR20120107025A (en) | Anti-obesity and anti-diabetes composition comprising oriental herbal extracts and fractions | |
KR101874458B1 (en) | Composition for preventing, improving or treating disorder associated with polycystic ovary syndrome comprising extract of Tetragonia tetragonoides as effective component | |
KR101543998B1 (en) | Composition for treating and improving fatty liver and hyperlipidemia comprising extract of olive as an active ingredient | |
KR20170055366A (en) | A composition for preventing or treating obesity comprising taraxacum coreanum root extract | |
KR100771987B1 (en) | Composition containing Bokbunja extract with testosterone secretion enhancing effect as an active ingredient | |
KR101732968B1 (en) | Pharmaceutical compositions for preventing or treating osteoporosis comprising an extract of Allium hookeri | |
KR20210131036A (en) | Composition for preventing or treating man subfertility comprising aurantii fructus immaturus as effective component | |
KR20190015423A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulae (Pf.). for treating or preventing metabolic disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: KOSA BIO INC., KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KONG, HYUN SEO;REEL/FRAME:059234/0883 Effective date: 20211217 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |